🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In 20 years, I've published 300+ papers: 41k+ citations. It all started with just 3 simple writing tips per section. The best researchers know this secret. Great papers tell great stories that keep readers hooked. How? Here's my academic storytelling framework:

Life expectancy increased in all countries of the world Of course, we learn from and respect our ancestors but let’s be real: their average life expectancy was 30. Not every “our ancestors did this” claim leads to good health today. Medicine isn’t about myths. It’s about

Breaking News from ph3 Embark trial👉Enzalutamide+ADT improve overall survival (OS) vs. ADT alone in Non-Metastatic HSPC #Prostatecancer Congrats to Stephen Freedland, MD neal shore & team! Earlier enza works better! Link👉 rb.gy/iyc3f2 OncoAlert UroToday.com Prostate Cancer Foundation

Treatment Algorithm: This is the algorithm we have used during our discussion w/ Deepa Rangachari, MD, FASCO for Stage I-III non-small cell #LungCancer #OncTwitter #MedTwitter #lcsm

Mismatch repair-deficient cancers 🧬🧬🧬 Immune-checkpoint inhibitors, turning genetic scars into long-lasting remission. NatureRevClinOncol OncoAlert Society for Immunotherapy of Cancer nature.com/articles/s4157…

N1 axillary disease post neoadjuvant chemo in Early Stage Breast Cancer? If clinically N0, SLNB with >= 3 nodes or TAD is fine. Residual ITCs: ALND can be avoided. Residual micromets: ALND could be avoided, still standard for TNBC. Residual macromets: ALND still standard.

Check out this recent paper on #InflammatoryBreastCancer, it examines the clinicogenomic characterization of #IBC. 👉pubmed.ncbi.nlm.nih.gov/40378057/ @npriedig Brittany Bychkovsky, MD jennifer bellon Tari King MD Eric Winer, MD Lynette Sholl Sara Tolaney Nancy Lin, MD Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 Romualdo Barroso, MD PhD

Pan-cancer human brain metastases atlas at single-cell resolution dlvr.it/TLw4ZN

🫁 Perioperative Immunotherapy in Resectable NSCLC 🫁 🌟 linical DMFS by Neoadjuvant or Adjuvant treatment and cancer stage at 18 months 💫 Neo- and Adjuvant 💫 Stage II and Stage IIIA

🫁 Eight ASCO Ecucational Books on Lung Cancer have been published. 🫁

Brain metastasis: From etiology to ecotypes dlvr.it/TLxJTF

Consistent & practice-changing! Talazoparib + Enzalutamide improves OS in HRR-deficient mCRPC. OS: 45.1 vs 31.1 months (HR 0.62). BRCA1/2+: 4-year OS 53% vs 23%. A new SoC is here. @asco @oncoalert #prostatecancer #oncology Neeraj Agarwal, MD, FASCO 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 The Lancet Advanced Prostate Cancer Consensus Conference LARVOL

Activating mutations in EGFR gene has revolutionized management of #LungCancer, enabling development of TKIs. New review on strategies to optimize treatment: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… Alfredo Addeo MD Maxime Borgeaud Timothée Olivier, MD Jair Bar Kaushal Parikh Jill Feldman Xiuning Le MD PhD OncoAlert

In high-risk prostate cancer, radiotherapy plus ADT significantly reduces the risk of distant metastasis compared to surgery-based approaches. However, post-metastasis survival does not differ between treatments. European Urology Oncology Daniel E Spratt OncoAlert Advanced Prostate Cancer Consensus Conference European Association of Urology (EAU)

Topo1-based ADCs are broadly seen as superior to MMAE-based ADCs but apparently not for every target or indication. 2 papers out last week showing comparable efficacy in gastric cancer for two different topo1 CLDN18.2 ADCs in "biomarker positive" patients but efficacy is

Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) caught me up on the last decade of #RCC research in 20 mins! ANZUP #anzup25

Treatment outcome of NSCLC patients with BRAFnon-V600Emutations: a retrospective, multicentre analysis within the nNGM Lung Cancer in Germany in ESMO Open. Different results with targeted therapies by mutation type even among non-V600E NSCLC. esmoopen.com/article/S2059-…

The FDA granted breakthrough therapy designation to first-line treatment with trastuzumab deruxtecan (Enhertu) plus pertuzumab (Perjeta) for unresectable or metastatic HER2+ #BreastCancer. Check out this CURE Today interview where Dr. Sara Tolaney (Sara Tolaney) discusses the

DESTINY-Gastric04: Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer nejm.org/doi/full/10.10…

Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis in ESMO Open. 229 pts, 169 treated with 1st line Tx, 68.6% PD-L1 high, 39.7% KRAS mut. Longer PFS and OS with ICIs+/-CT as compared to CT alone. esmoopen.com/article/S2059-…